Devroe Eric 4
4 · Acrivon Therapeutics, Inc. · Filed Mar 4, 2025
Insider Transaction Report
Form 4
Devroe Eric
Chief Operating Officer
Transactions
- Award
Stock Option (Right to Buy)
2025-03-01+140,540→ 140,540 totalExercise: $5.31Exp: 2035-02-28→ Common Stock (140,540 underlying)
Footnotes (1)
- [F1]Twenty-five percent (25%) of the shares subject to the option vest on March 1, 2026, and the remaining shares subject to the option vest in 36 substantially equal monthly installments thereafter, in each case subject to the Reporting Person's continuous service through each vesting date.